Skip to main
  1. Stocks
  2. Elanco Animal Health Inc
  3. Forecast
ELAN

ELAN Stock Forecast & Price Target

ELAN Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Elanco Animal Health is supported by a strong 2Q beat and raise, with revenue of $1,368M, adjusted EBITDA of $288M, and adjusted diluted EPS of $0.34 all topping consensus while gross margin expanded to ~57.7%. Its outlook is strengthened by accelerating demand in Zenrelia, Quattro, and Befrena, plus management’s confidence in a Next Wave innovation pipeline with five to six blockbuster potential approvals and $2B+ peak sales potential. The raised FY26 guidance for revenue, EBITDA, and EPS, along with price increases already visible in pet health and farm animal markets, suggests improving execution, margin expansion, and continued deleveraging.

Bears say

Elanco Animal Health is facing a negative fundamental setup as unfavorable regulatory and pipeline developments, along with differentiated competitor approvals, could weaken investor confidence and pressure future growth. Slower adoption of its 7 key blockbusters, rising cannibalization of existing products, and commoditization in K9 derm or K9 parasiticide markets may depress sales and EPS growth below expectations, while products such as Flea and worm chewable for dogs, Interceptor Plus, and Drontal Family appear vulnerable to share loss. Further uncertainty around product mix transition, pipeline execution, operational improvement plans, and weather, disease, and political risks adds to the downside as an independent company.

ELAN has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Elanco Animal Health Inc and is not a guaranteed prediction by Public.com or investment advice.

ELAN Analyst Forecast & Price Prediction

Get the latest ELAN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ELAN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Elanco Animal Health Inc (ELAN) Forecast

Analysts have given ELAN a Buy based on their latest research and market trends.

According to 11 analysts, ELAN has a Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $30.36, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $30.36, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Elanco Animal Health Inc (ELAN)


ELAN Analyst Forecast & Price Prediction

Get the latest ELAN stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in ELAN

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover ELAN stock data and trends